Ozempic, Wegovy, and Mounjaro Lawsuits: What Alabama Patients Need to Know

Ozempic (semaglutide), Wegovy (a higher-dose version of semaglutide), and Mounjaro (tirzepatide) are GLP-1 receptor agonists—injectable drugs originally developed to treat type 2 diabetes. In recent years, their use has exploded due to their effectiveness in producing rapid weight loss.

But with growing use has come growing concern. Lawsuits and patient reports suggest that manufacturers may not have adequately warned about serious risks—especially for those prescribed the drugs for weight loss off-label.

What Side Effects Are Being Reported?

Thousands of patients have reported life-altering complications, many of which required hospitalization or resulted in long-term damage.

Commonly reported complications include:

• Gastroparesis (stomach paralysis): a condition that slows or stops the movement of food from the stomach to the small intestine. It causes severe nausea, vomiting, bloating, and malnutrition.
• Intestinal blockage or ileus: some users required emergency surgery after experiencing a full blockage of the digestive tract.
• NAION (non-arteritic anterior ischemic optic neuropathy): a rare but serious eye condition that can lead to sudden and irreversible blindness.
• Gallbladder and bile duct disease: including inflammation, infection, and gallstones.
• Pancreatitis: painful inflammation of the pancreas that may require hospitalization.
• Chronic dehydration: from continuous vomiting and GI distress.

The FDA added a warning for intestinal blockage on semaglutide’s label in 2023. Yet many patients were never informed of the risk before using the drug.

Alabama Patients May Be Especially at Risk

These medications are prescribed widely across Alabama for both diabetes and weight loss. If you were prescribed Ozempic, Wegovy, or Mounjaro in Alabama and later experienced serious side effects, you may be eligible to file a legal claim.

What Are the Lawsuits About?

Thousands of individual lawsuits are now being consolidated in a federal multidistrict litigation (MDL 3094)—currently taking place in Pennsylvania.

The legal claims argue that:

• Drugmakers failed to provide proper warnings about serious side effects
• The risk of conditions like gastroparesis and NAION was minimized or omitted from the label
• Patients were harmed after using the drugs as prescribed
• Many individuals were prescribed these drugs off-label for weight loss without sufficient disclosure of risks

This is not a class action. Each case is reviewed individually, and patients can seek compensation based on their specific injuries.

What Kind of Compensation Is Available?

If you qualify, you may be entitled to compensation for:

• Medical bills and treatment costs
• Lost wages or inability to work
• Pain and suffering
• Permanent disability or loss of function
• Emotional distress
• Future medical care

Who Qualifies to File a Claim?

You may qualify if:

• You took Ozempic, Wegovy, or Mounjaro
• You developed a serious side effect such as gastroparesis, intestinal blockage, vision loss, or organ inflammation
• You were not properly warned of these risks before starting the medication